Institute of Nursing Science, University of Freiburg, Faculty of Medicine, Freiburg, Germany
Institute of Nursing Science, University of Freiburg, Faculty of Medicine, Freiburg, Germany.
BMJ Open. 2021 May 5;11(5):e044374. doi: 10.1136/bmjopen-2020-044374.
Self-management (SM) may facilitate patient participation and involvement to become active and knowledgeable partners in the care of complex chronic conditions such as ventricular assist device (VAD) therapy. The 'SM model for patients on VAD support' will serve to distinguish between SM components, and will guide the development, implementation and evaluation of an evidence-based curriculum.
This is a 3-phase, multicentre study. In phase 1, a prevalence study will be performed. Phase 2 aims to develop an evidence-based, interprofessional curriculum for SM support for VAD patients. In phase 3, a non-blinded block-randomised controlled trial (RCT), allocation ratio 1:1, intervention group superiority, with an unblinded multifacetted intervention with assessments before (T1) and after (T2) the intervention, and two follow-up assessments at three (T3), and 12 (T4) months after VAD implantation, will be performed. The curriculum guides the intervention in the RCT. Patient recruitment will consider centre-related volume: power analyses require 384 patients for phase 1, and 142 patients for phase 3.
Ethical considerations will be continuously taken into account and approved by the institutional review boards. Central ethical review board approval has been obtained by the Albert-Ludwigs University Freiburg. This study will be performed in concordance with the Declaration of Helsinki and the European data protection law. Publications will exclusively report aggregated data and will be distributed in the scientific community, and patient support groups. Report languages will be German and English.
NCT04234230 and NCT04526964; Pre-results.
自我管理(SM)可以促进患者的参与,使他们成为复杂慢性疾病(如心室辅助装置(VAD)治疗)护理的积极和知识渊博的伙伴。“VAD 支持患者的 SM 模型”将有助于区分 SM 成分,并指导基于证据的课程的开发、实施和评估。
这是一个 3 阶段、多中心的研究。在第 1 阶段,将进行一项患病率研究。第 2 阶段旨在为 VAD 患者的 SM 支持制定一个基于证据的、跨专业的课程。在第 3 阶段,将进行一项非盲、块随机对照试验(RCT),分配比例为 1:1,干预组优势,进行非盲多方面干预,在干预前(T1)和干预后(T2)进行评估,并在 VAD 植入后 3(T3)和 12(T4)个月进行两次随访评估。该课程指导 RCT 中的干预。患者招募将考虑中心相关的数量:需要 384 名患者进行第 1 阶段,需要 142 名患者进行第 3 阶段的研究。
将不断考虑伦理因素,并由机构审查委员会批准。阿尔伯特-路德维希大学弗莱堡分校已获得中央伦理审查委员会的批准。本研究将按照赫尔辛基宣言和欧洲数据保护法进行。出版物将专门报告汇总数据,并将在科学界和患者支持团体中分发。报告语言将是德语和英语。
NCT04234230 和 NCT04526964;预结果。